Fibrates Effect on Cardiovascular Risk Is Greater in Patients With High Triglyceride Levels or Atherogenic Dyslipidemia Profile: A Systematic Review and Meta-analysis
The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
According to recently published data, fibrates may reduce the risk of major cardiovascular events. Whether patients with low high-density lipoprotein cholesterol (HDL-C), high triglyceride levels, or both may have additional benefits remains under debate.We performed a meta-analysis of the 5 large trials assessing the impact of fibrates on cardiovascular end points and providing information on low HDL-C and high triglyceride levels. Subgroups were determined according to values closest to predetermined cut-offs for both HDL-C and triglycerides (<35 and >200 mg/dL, respectively). Overall, 4671 patients (2401 in fibrate group and 2270 in placebo group) were classified as having an atherogenic dyslipidemia featuring low HDLC combined with high triglyceride levels. Across trials, the proportion of patients classified in this subgroup ranged from 11% to 33%. We found a significant difference in the magnitude of fibrate effect across dyslipidemia subgroups (P for between-group heterogeneity = 0.0002). A greater effect size was found in patients with high triglyceride levels or atherogenic dyslipidemia phenotype where fibrates were estimated to reduce the cardiovascular risk by 28% [95% confidence interval (CI), 15% to 39%; P < 0.001] or 30% (95% CI, 19% to 40%, P < 0.0001), respectively, but only by 6% (95% CI, 22% to 13%, P = 0.13) in nonatherogenic dyslipidemia patients. Targeting patients with high triglyceride levels or atherogenic dyslipidemia with fibrates may help reduce residual vascular risk.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Potential use of fibrates to reduce TG levels is quite limited, due to the risk of myopathy if given with statins and the little benefit demonstrated in RCTs, aside from sub-group analysis including subjects with very high TG levels.200,270,271”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [271]
In the citing paper
“Results from other meta-analyses suggest reduced major CVD events in patients with high TGs and low HDL-C in fibrate-treated patients, but no decrease in CVD or total mortality.”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [272]
Citations
Cites
Yusuf, S., Hawken, S., Ôunpuu, S., Dans, T., Avezum, A., Lanas, F., McQueen, M., Budaj, A., Pais, P., Varigos, J., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17018-9 · Cited by 12,026
Helsinki Heart Study: Primary-Prevention Trial with Gemfibrozil in Middle-Aged Men with Dyslipidemia
Frick, M. H., Elo, O., Haapa, K., Heinonen, O. P., Heinsalmi, P., Helo, P., Huttunen, J. K., Kaitaniemi, P., Koskinen, P., Manninen, V., et al. (1987) · New England Journal of Medicine · doi:10.1056/nejm198711123172001 · Cited by 3,881
Rubins, H. B., Robins, S. J., Collins, D., Fye, C. L., Anderson, J. W., Elam, M. B., Faas, F. H., Linares, E., Schaefer, E. J., Schectman, G., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199908053410604 · Cited by 3,439 · cited 1×
“In one of the trials included, all randomized patients had a low HDL-C at randomization (,40 mg/dL).(11) We therefore performed the subgroup analysis according to triglyceride levels to discriminate the atherogenic dyslipidemia subgroup.”
MethodEffects of Combination Lipid Therapy in Type 2 Diabetes Mellitus
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001282 · Cited by 2,837
Nordestgaard, B. G., Benn, M., Schnohr, P., & Tybjærg-Hansen, A. (2007) · JAMA · doi:10.1001/jama.298.3.299 · Cited by 2,058 · cited 1×
“Moreover, it may also be that nonfasting triglyceride levels, measured 2–4 hours postprandially, may be of greater relevance to cardiovascular risk because atherogenic lipoprotein remnants secreted by the liver and intestine circulate in higher concentrations than in the fasting state.(28,29) However, hypoHDLemia can…”
BackgroundClofibrate and Niacin in Coronary Heart Disease
(1975) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1975.03240160024021 · Cited by 1,747
Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women
Bansal, S., Buring, J. E., Rifai, N., Mora, S., Sacks, F. M., & Ridker, P. M. (2007) · JAMA · doi:10.1001/jama.298.3.309 · Cited by 1,619 · cited 1×
“Moreover, it may also be that nonfasting triglyceride levels, measured 2–4 hours postprandially, may be of greater relevance to cardiovascular risk because atherogenic lipoprotein remnants secreted by the liver and intestine circulate in higher concentrations than in the fasting state.(28,29) However, hypoHDLemia can…”
BackgroundSarwar, N., Danesh, J., Eiriksdottir, G., Sigurdsson, G., Wareham, N., Bingham, S., Boekholdt, S. M., Khaw, K.-T., & Gudnason, V. (2007) · Circulation · doi:10.1161/circulationaha.106.637793 · Cited by 1,408 · cited 1×
“These results are in line with recent studies and meta-analysis on the role of triglyceride in cardiovascular disease.(25) Moreover, it may also be that nonfasting triglyceride levels, measured 2–4 hours postprandially, may be of greater relevance to cardiovascular risk because atherogenic lipoprotein remnants secrete…”
ResultManninen, V, Tenkanen, L., Koskinen, P., Huttunen, J. K., Mänttäri, M., Heinonen, O. P., & Frick, M. H. (1992) · Circulation · doi:10.1161/01.cir.85.1.37 · Cited by 1,329 · cited 3×
“The mean baseline HDL-C ranged from 32 to 47 mg/dL.(12,21) The trial with a lower mean baseline HDL-C(12) was designed to assess the effect of fibrate in patients with low”
BackgroundMethodEffects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis
Jun, M., Foote, C., Lv, J., Neal, B., Patel, A., Nicholls, S. J., Grobbee, D. E., Cass, A., Chalmers, J., & Perkovic, V. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60656-3 · Cited by 927 · cited 2×
“Despite contrasting results on cardiovascular and cerebrovascular prevention,(4,5) a recently published meta-analysis including more than 45,000 individuals suggests that therapy with fibrates could reduce the risk of major cardiovascular events, mainly as a consequence of coronary events reduction.(6) Besides this ov…”
Robins, S. J., Collins, D., Wittes, J. T., Papademetriou, V., Deedwania, P. C., Schaefer, E. J., McNamara, J. R., Kashyap, M. L., Hershman, J. M., Wexler, L. F., et al. (2001) · JAMA · doi:10.1001/jama.285.12.1585 · Cited by 921
Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy
Cannon, C. P., Steinberg, B. A., Murphy, S. A., Mega, J. L., & Braunwald, E. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.04.070 · Cited by 770 · cited 1×
“In this way, targeting low-density lipoprotein cholesterol (LDL-C) with statins has proved to be a particularly effective prevention strategy to reduce the risk of cardiovascular events.(1,2) However, an important residual risk may persist, highlighting the need to develop additional preventive therapies.”
BackgroundScott, R., O'Brien, R., Fulcher, G., Pardy, C., d'Emden, M., Tse, D., Taskinen, M.-R., Ehnholm, C., Keech, A., & on behalf of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study Investigators (2009) · Diabetes Care · doi:10.2337/dc08-1543 · Cited by 551
Briel, M., Ferreira-Gonzalez, I., You, J. J., Karanicolas, P. J., Akl, E. A., Wu, P., Blechacz, B., Bassler, D., Wei, X., Sharman, A., et al. (2009) · BMJ · doi:10.1136/bmj.b92 · Cited by 491
Clofibrate and niacin in coronary heart disease
(1975) · JAMA · doi:10.1001/jama.231.4.360 · Cited by 297
Bruckert, E., Labreuche, J., & Amarenco, P. (2010) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2009.12.023 · Cited by 273 · cited 1×
“We have recently conducted a meta-analysis with nicotinic acid and found a similar decrease in cardiovascular events, although populations and trial designs were different.(30) Nicotinic acid treatment impacts on several lipid and lipoprotein plasma concentrations with a stronger efficacy on HDL-C, triglycerides, and…”
ResultSelf-citationFruchart, J.-C., Sacks, F. M., Hermans, M. P., Assmann, G., Brown, W. V., Ceska, R., Chapman, M. J., Dodson, P. M., Fioretto, P., Ginsberg, H. N., et al. (2008) · Diabetes and Vascular Disease Research · doi:10.3132/dvdr.2008.046 · Cited by 260
Fruchart, J.-C. (2009) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2009.03.008 · Cited by 233 · cited 2×
“Fibrates have an effect on both the lipid levels and the inflammatory parameter.(8,27).”
BackgroundAssmann, G., Schulte, H., Cullen, P., & Seedorf, U. (2007) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.2007.01888.x · Cited by 213
Bezafibrate in men with lower extremity arterial disease: randomised controlled trial
Meade, T., Zuhrie, R., Cook, C., & Cooper, J. (2002) · BMJ · doi:10.1136/bmj.325.7373.1139 · Cited by 208
Corvol, J.-C., Bouzamondo, A., Sirol, M., Hulot, J.-S., Sanchez, P., & Lechat, P. (2003) · Archives of Internal Medicine · doi:10.1001/archinte.163.6.669 · Cited by 161
Effect of Fibrates on Lipid Profiles and Cardiovascular Outcomes: A Systematic Review
Abourbih, S., Filion, K. B., Joseph, L., Schiffrin, E. L., Rinfret, S., Poirier, P., Pilote, L., Genest, J., & Eisenberg, M. J. (2009) · The American Journal of Medicine · doi:10.1016/j.amjmed.2009.03.030 · Cited by 139 · cited 2×
“Fibrates have an effect on both the lipid levels and the inflammatory parameter.(8,27).”
BackgroundSaha, S. A., Kizhakepunnur, L. G., Bahekar, A., & Arora, R. R. (2007) · American Heart Journal · doi:10.1016/j.ahj.2007.07.011 · Cited by 137
Labreuche, J., Deplanque, D., Touboul, P., Bruckert, É., & Amarenco, P. (2010) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2010.02.011 · Cited by 83
Self-citationAssmann, G., Schulte, H., & Seedorf, U. (2008) · International Journal of Obesity · doi:10.1038/ijo.2008.29 · Cited by 70
Gender differences in the lipid profile of dyslipidemic subjects
Kolovou, G. D., Anagnostopoulou, K. K., Damaskos, D. S., Bilianou, H. I., Mihas, C. C., Milionis, H. J., Kostakou, P. M., & Cokkinos, D. V. (2008) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2008.06.011 · Cited by 70 · cited 1×
“Moreover, according to gender differences about the impact of triglycerides and HDL-C, the cut-off values used here may not have been completely appropriate.(32) For all these reasons, designing a meta-analysis of individual data may help to discriminate possible confounding factors.”
BackgroundDyslipidaemia and global cardiovascular risk: clinical issues
Assmann, G. (2006) · European Heart Journal Supplements · doi:10.1093/eurheartj/sul040 · Cited by 28
Cited by
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz455 · Cited by 8,961
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.08.014 · Cited by 4,854
“Results from other meta-analyses suggest reduced major CVD events in patients with high TGs and low HDL-C in fibratetreated patients, but no decrease in CVD or total mortality.(314) 316 Thus, the overall efficacy of fibrates on CVD outcomes is much less robust than that of statins.”
Cosentino, F., Grant, P. J., Aboyans, V., Bailey, C. J., Ceriello, A., Delgado, V., Federici, M., Filippatos, G., Grobbee, D. E., Hansen, T. B., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz486 · Cited by 4,763
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Catapano, A. L., Graham, I., De Backer, G., Wiklund, O., Chapman, M. J., Drexel, H., Hoes, A. W., Jennings, C. S., Landmesser, U., Pedersen, T. R., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw272 · Cited by 3,162
(2013) · European Heart Journal · doi:10.1093/eurheartj/eht108 · Cited by 1,955
Metadata
- Authors
- Bruckert, E., Labreuche, J., Deplanque, D., Touboul, P.-J., & Amarenco, P.
- Affiliations
- Inserm (FR)
- Venue
- Journal of Cardiovascular Pharmacology
- Published
- 2011-02
- Volume
- 57
- Issue
- 2
- Pages
- 267-272
- ISSN
- 0160-2446 (ISSN-L)
- OpenAlex
- W2071298734
- Cited by
- 192
- References
- 30
- Citations by year
- 2026: 5 · 2025: 6 · 2024: 4 · 2023: 15 · 2022: 16 · 2021: 13 · 2020: 15 · 2019: 13 · 2018: 11 · 2017: 10 · 2016: 17 · 2015: 16 · 2014: 16 · 2013: 16 · 2012: 10
- FWCI
- 1.94
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Cardiovascular Pharmacology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- fibrates, cardiovascular risk, atherogenic dyslipidemia, low HDL cholesterol, cardiovascular events, subgroup analysis
- MeSH terms
- Cardiovascular Diseases, Humans, Risk Factors, Triglycerides, Dyslipidemias, Atherosclerosis, Fibric Acids
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.